about
Is early intervention in psychosis cost-effective over the long term?Enduring negative symptoms in first-episode psychosis: comparison of six methods using follow-up data.A controlled trial of cognitively oriented psychotherapy for early psychosis (COPE) with four-year follow-up readmission data.Study protocol: The development of a pilot study employing a randomised controlled design to investigate the feasibility and effects of a peer support program following discharge from a specialist first-episode psychosis treatment centre.The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): study protocol for a randomised control trial.Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial.Very low-dose risperidone in first-episode psychosis: a safe and effective way to initiate treatmentResearch priorities in suicide prevention in Australia. A comparison of current research efforts and stakeholder-identified priorities.Lifetime rates and correlates of crime victimisation in young people with mental ill-health.Pattern and correlates of inpatient admission during the initial acute phase of first-episode psychosis.Prediction of a single psychotic episode: a 7.5-year, prospective study in first-episode psychosis.Self reported rates of criminal offending and victimization in young people at-risk for psychosis.A comparison of the efficacy and safety of olanzapine and risperidone in the treatment of elderly patients with schizophrenia: an open study of six months duration.Road to full recovery: longitudinal relationship between symptomatic remission and psychosocial recovery in first-episode psychosis over 7.5 years.Pre-morbid and outcome correlates of first episode mania with psychosis: is a distinction between schizoaffective and bipolar I disorder valid in the early phase of psychotic disorders?The EPPIC follow-up study of first-episode psychosis: longer-term clinical and functional outcome 7 years after index admission.The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia.Pattern of lifetime Axis I morbidity among a treated sample of first-episode psychosis patients.Demographic and clinical characteristics of young people seeking help at youth mental health services: baseline findings of the Transitions Study.Youth Depression Alleviation-Augmentation with an anti-inflammatory agent (YoDA-A): protocol and rationale for a placebo-controlled randomized trial of rosuvastatin and aspirin.Long-term follow-up of all-cause and unnatural death in young people with first-episode psychosis.Outcome in early-onset schizophrenia revisited: findings from the Early Psychosis Prevention and Intervention Centre long-term follow-up study.Early Psychosis Prevention and Intervention Centre long-term follow-up study of first-episode psychosis: methodology and baseline characteristics.Substance misuse in first-episode psychosis: 15-month prospective follow-up study.Randomized controlled trial of a cannabis-focused intervention for young people with first-episode psychosis.Course of substance misuse and daily tobacco use in first-episode psychosis.Early intervention in first-episode psychosis--the impact of a community development campaign.Schneiderian first rank symptoms predict poor outcome within first episode manic psychosis.The combination of cognitive testing and an informant questionnaire in screening for dementia.Reduced awareness of illness in first-episode psychosis.Comparing correlated kappas by resampling: is one level of agreement significantly different from another?The inter-rater and test-retest reliabilities of prodromal symptoms in first-episode psychosis.The relationship between duration of untreated psychosis and outcome: an eight-year prospective study.Duration of untreated psychosis and 12-month outcome in first-episode psychosis: the impact of treatment approach.Does treatment delay in first-episode psychosis really matter?Acute-phase and 1-year follow-up results of a randomized controlled trial of CBT versus Befriending for first-episode psychosis: the ACE projectThe Credibility and Acceptability of Befriending as a Control Therapy in a Randomized Controlled Trial of Cognitive Behaviour Therapy for Acute First Episode PsychosisCognitively oriented psychotherapy for early psychosis (COPE): A 1-year follow-upDuration of untreated psychosis: definition, measurement and association with outcomeAntibodies to Infectious Agents in Individuals at Ultra-High Risk for Psychosis
P50
Q24649904-5B771C1C-585C-40C9-8CD4-58E32756FEE2Q30585254-EB6CD94D-9D20-4DAD-970B-31420F7251ABQ31005080-17A5BAEB-1DB8-4167-BBC5-ED12FDBC6E4CQ33586902-A7FE2C86-C67C-4173-9871-FB3DC50E7FAAQ33586902-E7A3DAFB-6226-45D9-B60F-362A22FC15C8Q34504812-EF9E6F67-10C7-4044-828D-78C09B737CB6Q34616402-48FD03A8-9CC4-4185-89DF-CE562D8CAE12Q36192422-7F66B390-DA1E-463F-B729-EE17674FB133Q37345318-9D5EA867-31D3-47BD-969C-033341975854Q39608392-855DF5CF-0F7E-473E-97E5-576E5261F751Q39754449-FDB889B8-402A-4AAF-837C-C6982233DF1DQ39816531-5F75C37C-8CD3-4BC3-92DD-30279CA105CCQ40876592-5F97BBA0-40F3-4675-B62E-6914F752F7B4Q42678187-30645E47-504D-47D7-94DD-E3D266FEACF9Q43474660-A3072502-3D88-49BA-BC4D-23AC478F58E8Q43885537-E14E723E-E03E-4AE8-A84E-7A2834174FFEQ43903437-0C8C8744-9383-4393-AC45-D463743BAD4BQ44453886-52407916-E15F-46A1-B838-B8D683119F4DQ44653086-2F1B5130-0D34-47A0-802E-9A2B1040F824Q44866482-A3E2A2B9-A09E-4CC4-BA55-6001A8D87DCDQ48071032-7A3EBEDD-A0C5-45ED-BF5E-8E80038D7001Q48227296-3B2DB221-5EA2-4476-A9C6-6CC5BB633C76Q48829928-346E8EAF-6863-49D0-A050-BDC08BE506F0Q51907519-F33D21AB-C94A-4591-A66A-5B014D3CAE1AQ51913084-A6026793-8BA5-4263-8BD9-8EE980FA6BB7Q51914949-634D3651-D60B-4426-9B0E-D2F4A56A5111Q51924062-7622A32D-556D-4A58-A194-0BBED2515DF5Q51933772-D876AE74-F688-4422-A1EB-8277654F7E67Q51937861-6102F6D4-DBAE-4295-8DC8-F1E449D0A06CQ51946873-56EA6C87-026F-4EF3-80A6-E1CE957ACE64Q51962074-24FE936F-32C3-4AA2-BE55-586D0B97D1B2Q52291763-A430BA4A-B139-4834-8EC5-5473E50B2C37Q52890600-801857FC-E914-4901-8560-796124164744Q52979549-36A876AC-7FB9-4830-A5AA-0DF8F2193207Q53542048-A12E86CA-89F1-4C33-85B8-90908771CA9FQ55036321-F9856FE4-BE9A-40F7-ACA6-37CEE8A6DFC4Q58410331-C6DA2E52-52EE-4384-82AF-5F56AD6C9991Q58410361-D176401D-C1E7-45E7-839D-91D60170B2A9Q58410401-3C3DFB7F-76D2-4F44-A833-DEA01EB66479Q59784174-767EC844-FD0A-4697-A52D-A56C90DA5512
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Susy Harrigan
@ast
Susy Harrigan
@en
Susy Harrigan
@es
Susy Harrigan
@nl
Susy Harrigan
@sl
type
label
Susy Harrigan
@ast
Susy Harrigan
@en
Susy Harrigan
@es
Susy Harrigan
@nl
Susy Harrigan
@sl
altLabel
Susan Margaret Harrigan
@en
prefLabel
Susy Harrigan
@ast
Susy Harrigan
@en
Susy Harrigan
@es
Susy Harrigan
@nl
Susy Harrigan
@sl
P106
P1153
19734036400
P21
P31
P496
0000-0002-1384-3969
P569
2000-01-01T00:00:00Z